Physician profile
John Wallis
NPI 1639734569
$1,572.80
in general payments reported to CMS, 2019-2025
17 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.32 · 2023: $119 · 2024: $1,209 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $421.25 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Janssen Scientific Affairs, LLC | $200.84 | 2024 | Xarelto |
| Shockwave Medical, INC | $190.18 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $161.42 | 2024 | Symplicity G3, Cobalt Dr Mri Surescan |
| Amgen INC. | $138.92 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $119.70 | 2025 | Dupixent |
| Chiesi USA, INC. | $77.10 | 2023-2024 | Cleviprex, Kengreal |
| Astrazeneca Pharmaceuticals Lp | $38.06 | 2023 | Farxiga |
| Atricure, INC. | $35.89 | 2024 | |
| Glaxosmithkline, LLC. | $31.01 | 2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $28.97 | 2024 | |
| Alnylam Pharmaceuticals INC. | $28.51 | 2023 | Amvuttra |
| Pfizer INC. | $28.41 | 2022-2023 | |
| Genentech USA, INC. | $23.49 | 2025 | Xolair |
| Angiodynamics, INC. | $17.39 | 2025 | Alphavac |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2022 | |
| Abiomed | $15.44 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.